Balyasny Asset Management’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$845K Sell
102,041
-3,834
-4% -$45.2K ﹤0.01% 2307
2026
Q2
$1.42M Sell
105,875
-129,240
-55% -$1.69M ﹤0.01% 2005
2026
Q1
$3.14M Buy
+235,115
New +$3.3M ﹤0.01% 1579

Other funds holding RNA

Balyasny Asset Management's RNA Position: Q3 2026 in Review

Balyasny Asset Management reduced its Atrium Therapeutics (RNA) stake by 3.6% in Q3 2026, selling an estimated $45.2K and leaving 102,041 shares worth $845K. The position accounts for ﹤0.01% of the portfolio, ranked #2307.

Balyasny Asset Management first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.14M in Q1 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Balyasny Asset Management held 102,041 shares of Atrium Therapeutics worth $845K as of Q3 2026.
  • Balyasny Asset Management sold 3,834 Atrium Therapeutics shares in Q3 2026, an estimated $45.2K.
  • Atrium Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q3 2026, its #2307 holding.
  • Balyasny Asset Management first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Balyasny Asset Management's Atrium Therapeutics position peaked at $3.14M in Q1 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.